Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Fintel reports that on February 7, 2025, Piper Sandler upgraded their outlook for Nevro (NYSE:NVRO) from Underweight to ...

Globus Medical is acquiring Nevro Corp, a spinal cord stimulator company, according to a Feb. 6 news release. Globus Medical's transaction will include all shares of Nevro, which are valued at about ...

During the fourth quarter, NVRO announced the publication of new data demonstrating that Nevro’s SI Joint Fusion System (Nevro1) offers significant advantages over traditional approaches ...

Nevro NVRO is well-poised for growth in the ... The company also received CE Mark Certification in Europe for its HFX iQ SCS system, integrating AI technology to enhance competitiveness and ...

Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza ® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic ...

Globus Medical expects the Nevro acquisition to be accretive to its earnings in the second year of operation. Globus Medical expects to report full financial results for 2024 and provide its updated ...

Nevro's comprehensive HFXTM spinal cord stimulation (SCS) platform includes the Senza ® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful ...